★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
AstraZeneca PLC (AZN) Moat Analysis
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
AstraZeneca PLC generated $30.672 billion of H1 2026 Total Revenue: Oncology 46.0%, CVRM 19.9%, Rare Disease 16.0%, Respiratory & Immunology 15.5%, Other Medicines 1.6%, and Infectious Disease 1.0%. Its verified company-specific barrier is the patent and regulatory-exclusivity portfolio around marketed medicines; clinical and regulatory development requirements are industry-wide and are not counted separately. The barrier is strongest across the renewed Oncology, R&I and Rare Disease portfolios, but remains medium-duration because protection is product- and jurisdiction-specific. CVRM is fragile at the current mix: Farxiga represented about two-thirds of segment Product Revenue and faced US loss of exclusivity, multiple generic launches and active patent challenges. Soliris biosimilar erosion and Symbicort and Lynparza generic pressure provide additional live counterevidence.
Primary segment
Oncology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
6 segments · 6 tags
Updated 2026-08-23
Segments
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Revenue
46%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Cardiovascular, Renal and Metabolism (CVRM)
CVRM therapeutics (diabetes, CKD, heart failure, cardiovascular and metabolic diseases)
Revenue
19.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Respiratory & Immunology (R&I)
Respiratory and immunology therapeutics (asthma/COPD, immunology and inflammation)
Revenue
15.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Infectious Disease
Infectious disease therapeutics and prophylaxis, including vaccines and immune therapies
Revenue
1%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Rare Disease
Rare disease therapeutics (specialty/orphan indications, often biologics)
Revenue
16%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Other Medicines
Mature branded medicines outside core therapy areas (often facing generic competition)
Revenue
1.6%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Oncology $14,124m / Total Revenue $30,672m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivity protect multiple large oncology medicines, but protection is product- and jurisdiction-specific rather than a permanent segment-wide barrier. Current generic pressure on Lynparza and live patent proceedings temper durability.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent litigation losses or settlements
- Biosimilar entry after loss of exclusivity
- Regulatory/policy actions weakening IP protections
Leading indicators
- Patent challenge outcomes and injunctions
- Biosimilar applications/approvals in major markets
- Policy changes affecting patent/exclusivity regimes
Counterarguments
- IP can be challenged, narrowed, or designed around
- Fast followers can capture share quickly at LOE
Cardiovascular, Renal and Metabolism (CVRM)
CVRM therapeutics (diabetes, CKD, heart failure, cardiovascular and metabolic diseases)
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Cardiovascular, Renal & Metabolism $6,089m / Total Revenue $30,672m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent and regulatory protection still cover newer CVRM medicines, but the segment is currently dominated by Farxiga, whose US loss of exclusivity and multi-market generic entry make the aggregate barrier fragile.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and earlier-than-expected generic entry
- Reference pricing and reimbursement tightening
- Class-level competition reducing effective pricing
Leading indicators
- Patent litigation docket and outcomes
- Generic filings/approvals in major markets
- Net-to-gross and rebate trends
Counterarguments
- Competitors can win share via outcomes evidence and payer contracting
- Large markets attract aggressive generic/biosimilar entry post-LOE
Respiratory & Immunology (R&I)
Respiratory and immunology therapeutics (asthma/COPD, immunology and inflammation)
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Respiratory & Immunology $4,750m / Total Revenue $30,672m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivity protect newer biologics and combination medicines, while current growth in Fasenra, Breztri, Tezspire and Saphnelo supports a meaningful portfolio barrier. Symbicort generic entry and payer pressure limit durability.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar entry for biologics
- Patent invalidation or narrow claim construction
- Inhaled therapy commoditization
Leading indicators
- Biosimilar pipeline activity and approvals
- Patent challenge outcomes
- Net price and volume mix trends
Counterarguments
- Competitors can match mechanisms within a few years
- Payers can force rapid switching to preferred alternatives
Infectious Disease
Infectious disease therapeutics and prophylaxis, including vaccines and immune therapies
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Infectious Disease $312m / Total Revenue $30,672m. No standalone company-specific moat is established for this small alliance- and procurement-heavy portfolio.
Insufficient segment-specific evidence to assign a moat claim.
Rare Disease
Rare disease therapeutics (specialty/orphan indications, often biologics)
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Rare Disease $4,911m / Total Revenue $30,672m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
IP and regulatory exclusivity support Ultomiris, Strensiq and other rare-disease medicines, but current Soliris biosimilar erosion demonstrates that protection is finite and product-specific.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar erosion after LOE
- Patent challenges and earlier-than-expected entry
- Policy pressure to limit IP protections
Leading indicators
- Biosimilar approvals and tender outcomes
- Patient conversion dynamics within the franchise
- IP litigation outcomes in major markets
Counterarguments
- Biosimilars can scale quickly via hospital tender channels
- Switching can occur if payers mandate lower-cost alternatives
Other Medicines
Mature branded medicines outside core therapy areas (often facing generic competition)
Revenue share is exact from AstraZeneca H1 2026 Total Revenue by Therapy Area: Other Medicines $486m / Total Revenue $30,672m; generic erosion leaves no separately verified moat.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
A robust system for obtaining, maintaining and enforcing patents is a critical pillar of a sustainable innovation ecosystem.
The filing identifies enforceable patents as central to returns on long, costly and failure-prone drug development.
Affected by generic competition in China and VBP implementation
Lynparza faced current generic and price-policy pressure in China; the filing also discloses active patent proceedings for Lynparza and Tagrisso.
Multiple generics launched in Q2 2026
Farxiga represented about two-thirds of CVRM Product Revenue and declined 11% at constant exchange rates in H1 2026.
In February 2026, the Polish Patent Office invalidated one of AstraZeneca's patents covering Forxiga.
AstraZeneca is appealing, but the decision is direct current evidence of product-level IP erosion.
Market leader in ICS/LABA class with increasing generic competition
Symbicort declined 4% at constant exchange rates while newer protected R&I medicines grew, showing both portfolio renewal and active erosion.
Showing 5 of 6 sources.
Risks & Indicators
Erosion risks
- Patent litigation losses or settlements
- Biosimilar entry after loss of exclusivity
- Regulatory/policy actions weakening IP protections
- Compulsory licensing in certain jurisdictions
- Patent challenges and earlier-than-expected generic entry
- Reference pricing and reimbursement tightening
Leading indicators
- Patent challenge outcomes and injunctions
- Biosimilar applications/approvals in major markets
- Policy changes affecting patent/exclusivity regimes
- Patent litigation docket and outcomes
- Generic filings/approvals in major markets
- Net-to-gross and rebate trends
Research AZN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.